The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Circulating small extracellular vesicles in Alzheimer’s disease: a case–control study of neuro-inflammation and synaptic dysfunction
Open accessAbstract
Background: Alzheimer’s disease (AD) is a neurodegenerative disease characterized by Aβ plaques and neurofibrillary tangles. Chronic inflammation and synaptic dysfunction lead to disease progression and cognitive decline. Small extracellular vesicles (sEVs) are implicated in AD progression by facilitating the spread of pathological proteins and inflammatory cytokines. This study investigates synaptic dysfunction and neuroinflammation protein markers in plasma-derived sEVs (PsEVs), their association with Amyloid-β and tau pathologies, and their correlation with AD progression. Methods: A total of 90 [AD = 35, mild cognitive impairment (MCI) = 25, and healthy age-matched controls (AMC) = 30] participants were recruited. PsEVs were isolated using a chemical precipitation method, and their morphology was characterized by transmission electron microscopy. Using nanoparticle tracking analysis, the size and concentration of PsEVs were determined. Antibody-based validation of PsEVs was done using CD63, CD81, TSG101, and L1CAM antibodies. Synaptic dysfunction and neuroinflammation were evaluated with synaptophysin, TNF-α, IL-1β, and GFAP antibodies. AD-specific markers, amyloid-β (1–42), and p-Tau were examined within PsEVs using Western blot and ELISA. Results: Our findings reveal higher concentrations of PsEVs in AD and MCI compared to AMC (p < 0.0001). Amyloid-β (1–42) expression within PsEVs is significantly elevated in MCI and AD compared to AMC. We could also differentiate between the amyloid-β (1–42) expression in AD and MCI. Similarly, PsEVs-derived p-Tau exhibited elevated expression in MCI compared with AMC, which is further increased in AD. Synaptophysin exhibited downregulated expression in PsEVs from MCI to AD (p = 0.047) compared to AMC, whereas IL-1β, TNF-α, and GFAP showed increased expression in MCI and AD compared to AMC. The correlation between the neuropsychological tests and PsEVs-derived proteins (which included markers for synaptic integrity, neuroinflammation, and disease pathology) was also performed in our study. The increased number of PsEVs correlates with disease pathological markers, synaptic dysfunction, and neuroinflammation. Conclusions: Elevated PsEVs, upregulated amyloid-β (1–42), and p-Tau expression show high diagnostic accuracy in AD. The downregulated synaptophysin expression and upregulated neuroinflammatory markers in AD and MCI patients suggest potential synaptic degeneration and neuroinflammation. These findings support the potential of PsEV-associated biomarkers for AD diagnosis and highlight synaptic dysfunction and neuroinflammation in disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Instead, ongoing clinical trial studies are investigating EVs’ cargo, such as Aβ and tau proteins, for potential AD markers, due to their superior sensitivity, specificity, and accessibility in saliva, blood, and other body fluids [224,225].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [225]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., Antoniou, A., Arab, T., Archer, F., Atkin‐Smith, G. K., et al. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1535750 · Cited by 11,099
The biology , function , and biomedical applications of exosomes
Kalluri, R., & LeBleu, V. S. (2020) · Science · doi:10.1126/science.aau6977 · Cited by 10,770
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Breijyeh, Z., & Karaman, R. (2020) · Molecules · doi:10.3390/molecules25245789 · Cited by 2,789
Pegtel, D. M., & Gould, S. J. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-111902 · Cited by 2,682
Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
Inflammation as a central mechanism in Alzheimer's disease
Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., & Lamb, B. T. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.014 · Cited by 2,253 · cited 1×
“IL-1β, a potent immunomodulating cytokine, has previously been identified as a trigger for various inflammatory mediators in astrocytes and neurons [76].”
BackgroundAmyloid Beta: Structure, Biology and Structure-Based Therapeutic Development
Chen, G.-F., Xu, T.-H., Yan, Y., Zhou, Y.-R., Jiang, Y., Melcher, K., & Xu, H. E. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.28 · Cited by 1,965
The Amyloid-β Pathway in Alzheimer’s Disease
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952
Role of neuroinflammation in neurodegeneration development
Zhang, W., Xiao, D., Mao, Q., & Xia, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01486-5 · Cited by 1,668
Neuroinflammation: The Devil Is in the Details
DiSabato, D. J., Quan, N., & Godbout, J. P. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13607 · Cited by 1,640
Research works printed but not linked: 3
- Goetzl EJ, Kapogiannis D, Schwartz JB, Lobach IV, Goetzl L, Abner EL, et al. Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer’s disease. FASEB J. 2016;30(12):4141–8. · DOI · Paper page
- Kim KY, Shin KY, Chang KA. GFAP as a potential biomarker for Alzheimer’s disease: a systematic review and meta-analysis. Cells. 2023;12(9):1309. · DOI · Paper page
- Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):6977. · DOI · Paper page
Cited by
Glial fibrillary acidic protein in Alzheimer’s disease: a narrative review
Leipp, F., Vialaret, J., Mohaupt, P., Coppens, S., Jaffuel, A., Niehoff, A., Lehmann, S., & Hirtz, C. (2024) · Brain Communications · doi:10.1093/braincomms/fcae396 · Cited by 100
Extracellular vesicles: translational research and applications in neurology
Manolopoulos, A., Yao, P. J., & Kapogiannis, D. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01080-z · Cited by 63
Dehghani, S., Ocakcı, O., Hatipoglu, P. T., Özalp, V. C., & Tevlek, A. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04825-5 · Cited by 50
Agnello, L., Gambino, C. M., Ciaccio, A. M., Salemi, G., Brighina, F., Ragonese, P., Piccoli, T., Blandino, V., Stefano, V. D., Cacciabaudo, F., et al. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120248 · Cited by 23
Gonul, C. P., Karaçiçek, B., & Genç, Ş. (2025) · Developmental Neurobiology · doi:10.1002/dneu.22984 · Cited by 18
Metadata
- Authors
- Singh, R., Rai, S., Bharti, P. S., Zehra, S., Gorai, P. K., Modi, G. P., Rani, N., Dev, K., Inampudi, K. K., Y., V. V., Chatterjee, P., Nikolajeff, F., & Kumar, S.
- Affiliations
- All India Institute of Medical Sciences (IN)
- Indian Institute of Technology BHU (IN)
- Jamia Millia Islamia (IN)
- Luleå University of Technology (SE)
- Corresponding author
- Kumar, Saroj
- ORCID
- Venue
- BMC Medicine
- Published
- 2024-06-20
- Volume
- 22
- Issue
- 1
- Pages
- 254-254
- ISSN
- 1741-7015 (ISSN-L)
- PMC
- PMC11188177
- OpenAlex
- W4399860075
- Cited by
- 28
- References
- 81
- Citations by year
- 2026: 13 · 2025: 14 · 2024: 1
- FWCI
- 3.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- BMC Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Council of Scientific and Industrial Research (09/006(0533)/2021-EMR-I)
- Department of Health Research , INDIA (YSS/2020/000158)
- Indian Council of Medical Research (2020-1194)
- Department of Health Research (GIA/2020/000595)
- Lulea University of Technology
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, small extracellular vesicles, plasma-derived extracellular vesicles, synaptic dysfunction, neuroinflammation, amyloid-beta, tau phosphorylation, synaptophysin, IL-1β, TNF-α, glial fibrillary acidic protein, mild cognitive impairment, disease progression biomarkers, CD63, CD81, TSG101, L1CAM
- MeSH terms
- Extracellular Vesicles, Neuroinflammatory Diseases, Aged, Aged, 80 and over, Alzheimer Disease, Female, Humans, Male, Middle Aged, Synapses, Biomarkers, Case-Control Studies, Amyloid beta-Peptides, tau Proteins, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Circulating small extracellular vesicles in Alzheimer’s disease: a case–control study of neuro-inflammation and synaptic dysfunction. https://app.cochat.ai/papers/10.1186/s12916-024-03475-z
- The paper
- Singh, R., Rai, S., Bharti, P. S., Zehra, S., Gorai, P. K., Modi, G. P., Rani, N., Dev, K., Inampudi, K. K., Y., V. V., Chatterjee, P., Nikolajeff, F., & Kumar, S. (2024). Circulating small extracellular vesicles in Alzheimer’s disease: a case–control study of neuro-inflammation and synaptic dysfunction. BMC Medicine. https://doi.org/10.1186/s12916-024-03475-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.